S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
Log in

Ceapro Stock Forecast, Price & News

-0.02 (-3.61 %)
(As of 03/4/2021 12:00 AM ET)
Today's Range
Now: $0.53
50-Day Range
MA: $0.59
52-Week Range
Now: $0.53
Volume81,800 shs
Average Volume70,050 shs
Market Capitalization$41.50 million
P/E Ratio26.75
Dividend YieldN/A
Ceapro Inc., a biotechnology company, engages in the development and commercialization of active ingredients in the United States, Germany, China, Canada, and internationally. It operates in two segments, The Active Ingredient Product Technology Industry and The Cosmeceutical Industry. The company is involved in the development and application of technology to the production of extracts and active ingredients from oats and other renewable plant resources. It adds value to its extracts by supporting their use in cosmeceutical, nutraceutical, and therapeutics products for humans and animals. The company's products include natural active ingredients comprising beta glucan, avenanthramides, oat powder, oat oil, oat peptides, and lupin peptides that are marketed to personal care, cosmetic, medical, and animal health industries through its distribution partners and direct sales; natural anti-aging skincare products; and veterinary therapeutic products, such as oat shampoos, ear cleansers, and dermal complexes/conditioners. Its products and technologies that are under research and development, or pre-commercial stage comprise a platform using its beta glucan formulations to deliver compounds for treatments in the personal and healthcare sectors; various novel enabling technologies, such as Pressurized Gas eXpanded drying technology; and technologies to enhance the content of avenanthramides. The company has a collaboration with the McMaster University to develop inhalable therapeutic for COVID-19. Ceapro Inc. was incorporated in 1997 and is headquartered in Edmonton, Canada.
Ceapro logo


Is It Time To Consider Buying Ceapro Inc. (CVE:CZO)?
February 6, 2021 |  finance.yahoo.com
Ceapro Inc. to Present at NobleCon17
January 14, 2021 |  finance.yahoo.com
How Much Is Ceapro's (CVE:CZO) CEO Getting Paid?
December 23, 2020 |  finance.yahoo.com
How Much Did Ceapro Inc.'s (CVE:CZO) CEO Pocket Last Year?
November 18, 2019 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Year FoundedN/A



Sales & Book Value

Annual Sales$9.71 million
Book Value$0.22 per share


Net Income$-850,000.00


Market Cap$41.50 million
Next Earnings Date4/15/2021 (Estimated)
OptionableNot Optionable


Overall MarketRank

0.79 out of 5 stars

Medical Sector

1164th out of 1,969 stocks

Pharmaceutical Preparations Industry

527th out of 772 stocks

Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -
-0.02 (-3.61 %)
(As of 03/4/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CRPOF News and Ratings via Email

Sign-up to receive the latest news and ratings for CRPOF and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Ceapro (OTCMKTS:CRPOF) Frequently Asked Questions

What stocks does MarketBeat like better than Ceapro?

Wall Street analysts have given Ceapro a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Ceapro wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Ceapro?

Ceapro saw a increase in short interest in the month of February. As of February 12th, there was short interest totaling 55,900 shares, an increase of 203.8% from the January 28th total of 18,400 shares. Based on an average daily trading volume, of 186,200 shares, the days-to-cover ratio is presently 0.3 days.
View Ceapro's Short Interest

When is Ceapro's next earnings date?

Ceapro is scheduled to release its next quarterly earnings announcement on Thursday, April 15th 2021.
View our earnings forecast for Ceapro

How has Ceapro's stock been impacted by Coronavirus?

Ceapro's stock was trading at $0.1909 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, CRPOF shares have increased by 180.1% and is now trading at $0.5347.
View which stocks have been most impacted by COVID-19

Who are Ceapro's key executives?

Ceapro's management team includes the following people:
  • Mr. Gilles R. Gagnon M.B.A., M.Sc., MBA, ICD.D, CEO, Pres & Director (Age 67)
  • Ms. Stacy Prefontaine CPA, CA, CFO & Corp. Sec.
  • Dr. Bernhard Seifried, Sr. Director of Research & Technology

Who are some of Ceapro's key competitors?

What is Ceapro's stock symbol?

Ceapro trades on the OTCMKTS under the ticker symbol "CRPOF."

How do I buy shares of Ceapro?

Shares of CRPOF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ceapro's stock price today?

One share of CRPOF stock can currently be purchased for approximately $0.53.

How much money does Ceapro make?

Ceapro has a market capitalization of $41.50 million and generates $9.71 million in revenue each year.

What is Ceapro's official website?

The official website for Ceapro is www.ceapro.com.

Where are Ceapro's headquarters?

Ceapro is headquartered at 7824 51 Avenue NW, Edmonton A0, T6E 6W2.

How can I contact Ceapro?

Ceapro's mailing address is 7824 51 Avenue NW, Edmonton A0, T6E 6W2. The company can be reached via phone at 780-421-4555 or via email at [email protected]

This page was last updated on 3/5/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.